SCHEMBL4699408

SCHEMBL4699408

COc1ccc(-n2ncc3c(Nc4cc(C(=O)Nc5cccc(C(F)(F)F)c5)ccc4Cl)ncnc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
TP53 P04637 2/20 0.53
LMNA P02545 2/20 0.53
GAA P10253 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
THRB P10828 1/20 0.53
MAPK14 Q16539 7/20 0.52
NTRK1 P04629 1/20 0.52
PIP4K2A P48426 1/20 0.51
PIK3CG P48736 1/20 0.51
PIP4K2C Q8TBX8 1/20 0.51
BRAF P15056 4/20 0.51
RXFP1 Q9HBX9 1/20 0.49
DYRK3 O43781 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697666 0.94 PIP4K2A (0.53) MAPTTP53LMNAGAAKDM4E
SCHEMBL4789574 0.92 MAPK14 (0.63) MAPTTP53LMNAGAAKDM4E
SCHEMBL4917652 0.90 MAPT (0.62) MAPTTP53LMNAGAAKDM4E
SCHEMBL4755211 0.88 MAPT (0.62) MAPTTP53LMNAGAAKDM4E
SCHEMBL4187241 0.86 MAPK14 (0.57) MAPTTP53LMNAGAAKDM4E
SCHEMBL4919350 0.86 MAPT (0.54) MAPTTP53LMNAGAAKDM4E
SCHEMBL4917379 0.83 MAPT (0.62) MAPTTP53LMNAGAAKDM4E
SCHEMBL4754428 0.80 RXFP1 (0.47) MAPTTP53LMNAGAAKDM4E
SCHEMBL4751395 0.80 BRAF (0.62) MAPK14BRAFDYRK3LCKCSF1R
SCHEMBL4697939 0.79 BRAF (0.54) MAPTLMNAMEN1KMT2AMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US claimed
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP claimed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO claimed
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 MAPT 2142/4885TP53 1255/4885LMNA 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.